Why Dr. Elsa Wagner from Pierre Fabre chose Prometheus Panta for mAbs developability assessment

August 19, 2024

Developability assessment is essential for selecting the best monoclonal antibodies (mAbs) candidates for clinical development.

Dr. Elsa Wagner, a senior discovery scientist at Pierre Fabre Laboratories in France, focuses on putting together a comprehensive developability platform for monoclonal antibodies (mAbs) in immuno-oncology. To achieve this, Dr. Wagner needs precise methods to assess key stability parameters, such as thermal unfolding, particle sizing, and aggregation. Faced with large libraries of potential candidates, her priority is to obtain highly accurate and reproducible data for confident decision-making.

In this testimonial, read why she chose the Prometheus Panta instrument for simultaneous measurements of Dynamic Light Scattering (DLS), Differential Scanning Fluorimetry (nanoDSF), Static Light Scattering (SLS), and backreflection.

You’ll learn about:

How Pierre Fabre Laboratories approaches developability assessment for mAbs candidates

The criteria that guided her decision for the Prometheus Panta as a solution for her developability platform

The benefits of combining simultaneous thermal and colloidal stability measurements for confident ranking of mAbs candidates

For more details about Elsa's work with Prometheus Panta, read this case study.

Previous Video

De-risk your antibody characterization workflows with high-quality, multi-parameter stability data from Prometheus Panta

Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform o...

Up next

Biologics Formulation: Select optimal buffer conditions with multi-parameter stability characterization from Prometheus Panta

Learn how to identify optimal buffer conditions during pre-formulation, with multi-parameter stability char...

Want to see more
biologics content?

Explore resources

Return to education center

Why Dr. Elsa Wagner from Pierre Fabre chose Prometheus Panta for mAbs developability assessment

Previous Video

Up next

See more related content

Watch this webinar about approaches and insights into bispecific formulation development and screening with Prometheus Panta for thermal and colloidal stability characterization of biotherapeutics.

Learn how Pierre Fabre uses multi-parameter stability measurements of mAb libraries on Prometheus Panta to streamline developability platforms, reducing complexity, cost, and sample consumption.

Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.

Learn how to identify optimal buffer conditions during pre-formulation, with multi-parameter stability characterization from Prometheus Panta, a tool to collect thermal and colloidal data while saving

The work of pre-formulations scientists is critical to de-risk the entire development process for biologics. Read on to learn more about what to consider about your buffer components for...

Each excipient class helps stabilize biologics – from monoclonal antibodies to vaccine antigens – in different ways. Read on to learn more about some of the most important excipients for...

Characterize the developability of antibody-drug conjugates: Multi-parameter stability assessment with Prometheus Panta makes it possible to examine multiple aspects of ADC stability in parallel.

Learn how it’s possible to use the Prometheus Panta to extrapolate how your low concentration sample will behave once it’s scaled up and at higher concentrations used for clinical administration.

For antibody-drug conjugate (ADC) development, scientists rely on stability experiments using fluorescence and light scattering techniques to predict the conjugated molecule's behavior.

In this short animated video, learn the basics of how antibody-drug conjugates (ADCs) are engineered and why that makes them such powerful tools to target cancers with precision.

Antibody-drug conjugates, or ADCs, are revolutionary therapeutics that represent a growing proportion of the biologics market. They combine the targeting power of a monoclonal antibody, which is...

To assess the developability properties of antibody-drug conjugates (ADCs) learn about multi-parameter characterization of thermal and colloidal stability with Prometheus Panta using nanoDSF and DLS

Use this list of crowd-sourced favorites to kick-start your 2024 biologics conference plans. Find out when and where each conference takes place, who will be there, which topics are covered, and...

The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics

During early development of biologics, there are many attributes scientists evaluate for developability. Measure them with biophysical characterization using nanoDSF, DLS, backreflection, and SLS.

Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fisher Scientific approaches stability assessment of biologic, and how the Prometheus Panta helps

Thermal stability screening is a common approach used to study the developability of a wide range of protein-based therapeutics. Among the different technologies available to perform thermal stability

Learn about four methods for thermal stability measurements: DSC, CD, DSF and nanoDSF. You'll review their pros and cons, what they data tell you and why it's important for biologics developability.

Learn about Differential Scanning Calorimetry (DSC), Circular Dichroism (CD), Extrinsic Differential Scanning Fluorimetry, and nano-Differential Scanning Fluorimetry for thermal stability of proteins

Read this nanoDSF guide to learn how nano-Differential Scanning Fluorimetry (nanoDSF) uses your protein’s intrinsic fluorescence to determine its melting temperature, Tm and onset of melting, Ton.